Exploring Differentially Expressed Genes and Understanding the Underlying Mechanisms in Glioblastoma.

Area of Science:

• Neuro-oncology
• Molecular Biology
• Genomics

Background:

• Glioblastoma (GBM) is an aggressive brain tumor with poor prognosis.
• Current treatments show limited efficacy, necessitating new therapeutic strategies.
• Understanding GBM's molecular drivers is crucial for developing novel treatments.

Purpose of the Study:

• To compare transcriptomic profiles of GBM tissues and adjacent healthy tissues.
• To identify key molecular pathways and upstream regulators in GBM pathogenesis.
• To investigate early molecular changes preceding clinical symptoms.

Main Methods:

• Transcriptome analysis of 26 paired GBM and adjacent healthy tissues using the Ion GeneStudio S5 system.
• Histopathological examination for tissue confirmation.
• Ingenuity Pathway Analysis (IPA) for pathway and regulator identification.
• Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR) for validating upstream regulators.

Main Results:

• Dysregulated pathways were primarily linked to neuronal connections and neurotransmitter signaling.
• Expression patterns of identified upstream regulators aligned with RNA-sequencing (RNA-seq) data.
• Molecular alterations potentially initiate early in tumor development, prior to symptoms.

Conclusions:

• Transcriptomic comparison reveals significant pathway dysregulation in GBM.
• Identified pathways and regulators offer potential targets for early GBM detection and therapy.
• Further research is needed to elucidate the functional roles of identified upstream regulators in GBM.